Skip to content

ResMed

US · RMD #644 by market cap Listed 1970
235.63 -1.25 -0.53%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Price chart

Pre-market 237.57 +0.29%
After-hours 235.63 0.00%
Overnight 236.99 +0.05%
252.50181.79235.632026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on RMD?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +0.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 7.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall A
ValuationGrowthProfitMomentumHealthAnalyst
Valuation C+

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 21.5x Better than 38%
Forward P/E 19.4x Better than 38%
Price / Sales 5.8x Better than 19%
P/E vs own 5-yr range 7th pctl Better than 93%
Growth A-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 10.2% Better than 65%
Net income CAGR (3Y) 19.3% Better than 72%
Free cash flow CAGR (3Y) 42.8% Better than 82%
Profitability A

How much profit the business keeps from each dollar of sales and capital.

Gross margin 61.1% Better than 75%
Operating margin 33.8% Better than 92%
Net margin 26.9% Better than 87%
Return on equity 24.3% Better than 83%
Return on invested capital 21.4% Better than 91%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 2.1% Better than 78%
6-month return 13.9% Better than 77%
12-month return (ex latest month) 1.7% Better than 36%
Distance below 52-week high 14.2% Better than 74%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.1x Better than 74%
Debt to assets 9.2% Better than 71%
Interest coverage 28.7x Better than 86%
Free cash flow / net income 106.9% Better than 43%
Analyst View C-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 50.0% Better than 26%
Upside to average target 16.4% Better than 26%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -1.63%
1M -3.75%
3M +3.43%
6M +12.91%
YTD -1.10%
1Y -2.34%
3Y +60.43%
5Y -5.16%

Key statistics

Price & volume

Prev close
236.88
Open
237.18
Day range
234.70 - 242.43
Avg price
237.26
Volume
1.37M
Turnover
325.02M
Amplitude
3.26%
52-week range
179.25 - 274.65

Valuation

P/E
22.59
P/E (TTM)
21.46
P/B
5.57
EPS
10.43
Net profit
1.47B
Net assets
5.95B

Share structure

Market cap
33.14B
Float cap
32.94B
Shares out
140.66M
Float shares
139.80M

Dividend & listing

Dividend (TTM)
2.46
Listing date
1970-01-01
52-week range 59% of range
179.25 274.65

14.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-49.66M net over the window

Short interest

Shares short
10.47M
As of
2026-10-30

Frequently asked questions

What is the current stock price of ResMed (RMD)?

ResMed last traded at 235.63. This page shows a periodic quote snapshot. Check the displayed quote time.

What is ResMed's market cap?

About 33.14B.

What is the P/E ratio of ResMed?

The trailing twelve-month P/E is 21.46, below its own 5-year average of 34.19 — toward the bottom of its historical range (7.41% percentile). See the Valuation tab for the full history.

Does ResMed pay a dividend?

Yes. The trailing dividend yield is 1.04%. The 2025 payout was up 11.9% from 2024. See the Dividends tab for the full payment history.

Is ResMed a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 274.29, which implies 16.4% upside from the current price. This is not investment advice.

What is ResMed's StockVane Quant Rating?

The StockVane Momentum strategy currently rates ResMed a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:01:25 · For reference only, not investment advice and not tailored to your situation.

ResMed discussion 0 comments

Add a comment